Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 37Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Neoplasms 9Colorectal Neoplasms 9Thyroid Carcinoma, Anaplastic 8Neoplasm Metastasis 6Multiple Myeloma 5Glioma 5Pancreatic Neoplasms 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Recurrence 3Prostatic Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Hematologic Neoplasms 3Ameloblastoma 3Skin Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neurofibroma, Plexiform 2Myelodysplastic Syndromes 2Meningioma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Breast Neoplasms 2Astrocytoma 2

Interventions

trametinib 1selpercatinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1dabrafenib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Thyroid Cancer Patients Who Received Target Therapy × trametinib × Clear all
NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡